By Professor Adam Jaffe

Preprints

Umashankar B; Capraro A; Vijayan A; Wong SL; Nielsen BU; Zhong L; Raftery M; Allan K; Ooi CY; Sivam S; Visser S; Prentice BJ; Fawcett L; Kovacevic Z; Eliasson L; Faurholt-Jepsen D; Jaffe A; Shaw JA; Vafaee F; Waters SA, Serum Exosomal Multi-Omic Signatures Stratify Glucose Tolerance in Cystic Fibrosis and Reveal Partial Therapeutic Reprogramming by CFTR Modulators, http://dx.doi.org/10.1101/2025.07.07.25331056

Awatade NT; Wong SL; Pandzic E; Slapetova I; Capraro A; Zhong L; Turgutoglu N; Fawcett LK; Whan RM; Jaffe A; Waters SA, Significant functional differences despite morphological and molecular similarity in fully differentiated matched Conditionally Reprogrammed (CRC) and Feeder free dual SMAD inhibited expanded human nasal epithelial cells, http://dx.doi.org/10.1101/2020.05.29.120006

Singh J; Jaffe A; Schultz A; Selvadurai H, Surfactant Protein Deficiency Syndrome in Childhood Interstitial Lung Disease, http://dx.doi.org/10.22541/au.160037735.51250770

Chan C; Coffey M; Murphy C; McKay I; Abdu J; Paida K; Tam R; Wrigley-Carr H; Prentice B; Owens L; Belessis Y; Chuang S; Jaffe A; van Dorst J; Ooi CY, The Prevalence of pks+ E. coli in Cystic Fibrosis, http://dx.doi.org/10.20944/preprints202502.0874.v1

Stiboy E; Chan M; Islam MS; L GS; Lui K; Jaffe A; Homaira N, Variation in clinical practice guidelines for use of palivizumab in preventing severe respiratory syncytial viral (RSV) disease in high-risk infants, http://dx.doi.org/10.22541/au.166419726.62754781/v2

Stiboy E; Chan M; Islam MS; L GS; Lui K; Jaffe A; Homaira N, Variation in clinical practice guidelines for use of palivizumab in preventing severe respiratory syncytial viral (RSV) disease in high-risk infants, http://dx.doi.org/10.22541/au.166419726.62754781/v1

Other

Strachan RE; Jaffé A, 2011, Recommendations for managing paediatric empyema thoracis

Back to profile page